Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea

CURRENT STATUS: ACCEPTED

BMC Infectious Diseases  ▶ BMC Series

EUN LEE
Chonnam National University
ORCiD: 0000-0002-0145-7067

Chul-Hong Kim
Samsung Changwon Hospital

Yong Ju Lee
Hallym University College of Medicine

Hyo-Bin Kim
Inje University College of Medicine

Bong-Seong Kim
University of Ulsan College of Medicine

Hyung Young Kim
Pusan National University School of Medicine

Yunsun Kim
Soonchunhyang University Hospital

Sangyoung Kim
Soonchunhyang University Hospital

Chorong Park
Soonchunhyang University Hospital

Ju-Hee Seo
Dankook University Hospital

In Suk Sol
Hallym University Sacred Heart Hospital

Myongsoon Sung
Soonchunhyang University Hospital
DOI: 10.21203/rs.2.16836/v2

SUBJECT AREAS

Infectious Diseases

KEYWORDS

Children; Pneumonia; Respiratory virus; Mycoplasma pneumoniae; Macrolide-refractory; Macrolide-sensitive; Macrolide less-effective
Abstract

Background: Community-acquired pneumonia (CAP) is one of the leading worldwide causes of childhood morbidity and mortality. Its disease burden varies by age and etiology and is time dependent. We aimed to investigate the annual and seasonal patterns in etiologies of pediatric CAP requiring hospitalization. Methods: We conducted a retrospective study in 30,994 children (aged 0-18 years) with CAP between 2010 and 2015 at 23 nationwide hospitals in South Korea. Mycoplasma pneumoniae (MP) pneumonia was clinically classified as macrolide-sensitive MP, macrolide-less effective MP (MLEP), and macrolide-refractory MP (MRMP) based on fever duration after initiation of macrolide treatment, regardless of the results of in vitro macrolide sensitivity tests. Results: MP and respiratory syncytial virus (RSV) were the two most commonly identified pathogens of CAP. With the two epidemics of MP pneumonia (2011 and 2015), the rates of clinical MLEP and MRMP pneumonia showed increasing trends of 36.4% of the total MP pneumonia. In children < 2 years of age, RSV (34.0%) was the most common cause of CAP, followed by MP (9.4%); however, MP was the most common cause of CAP in children aged 2-18 years of age (45.3%). Systemic corticosteroid was most commonly administered for MP pneumonia. The rate of hospitalization in intensive care units was the highest for RSV pneumonia, and ventilator care was most commonly needed in cases of adenovirus pneumonia.

Conclusions: The present study provides fundamental data to establish public health policies to decrease the disease burden due to CAP and improve of pediatric health.

Background

Lower respiratory tract infections, including pneumonia, are a group of diseases that constitute a leading worldwide cause of pediatric morbidity, requiring hospitalization, and mortality [1, 2]. Childhood pneumonia causes diverse long-term sequelae, such as
restrictive or obstructive lung disease, as well as bronchiectasis, particularly in a considerable proportion of children hospitalized due to community-acquired pneumonia (CAP) [3].

The etiologies of CAP affect the disease burden, development of long-term sequelae, and mortality [3, 4]. The mortality, severity, and disease burden due to CAP differ by age [3, 5]. Therefore, prediction of the causative pathogens and clinical courses before the identification of respiratory pathogens in children with CAP is needed to improve disease outcomes. There are annual and seasonal variabilities in the respiratory pathogens that cause CAP. In addition, the characteristics of these pathogens, including susceptibility to antibiotics, change over time. Assessments of the annual and seasonal variabilities and pathogen characteristics could provide important information needed to establish a direction for vaccine development and health care policies. However, comprehensive studies on these topics are scarce.

The most common causes of pediatric CAP in high-income countries, which differ according to age, are *Mycoplasma pneumoniae* (MP) and respiratory viruses [6]. Epidemics of MP infections are repeated on a 3-7 year cycle; the last epidemic in Korea was in 2015 [7-9]. After 2000, macrolide-resistant MP pneumonia rapidly emerged, especially in Asia [7]. MP infections in children are often self-limiting, even in patients with macrolide-resistant MP pneumonia [10]. More than 80% of patients with macrolide-sensitive MP (MSMP) have shown defervescence within 48-72 hours after the initiation of macrolide treatment; this occurs in approximately 30% of patients with macrolide-resistant MP pneumonia [11]. Despite its high prevalence, large-scale epidemiologic studies of macrolide-resistant MP pneumonia are scarce.

In the present study, we aimed to identify the annual and seasonal patterns of respiratory pathogens in pediatric CAP requiring hospitalization and the prevalence of MP pneumonia
according to the clinical responses to macrolides. In addition, we compared the clinical characteristics according to respiratory pathogens in patients with pediatric CAP.

Methods

Study population

We conducted a retrospective chart review of children hospitalized with CAP between January 2010 and December 2015 in a cohort of children younger than 18 years of age from 23 medical centers in South Korea. During the study period, a total of 65,243 children were diagnosed with CAP based on clinical features, chest radiography, and laboratory findings. Among them, 30,994 children underwent real-time polymerase chain reaction (RT-PCR) analyses for respiratory virus (n=30,994) or MP (n=9,197), or underwent serology tests for MP (n=30,994), to identify the etiologies of CAP [7]. To identify differences in causative pathogens according to age, the enrolled children were divided into four age groups as follows: < 2 years, 2 years to <5 years, 5 years to <12 years, and 12 years to <18 years. Information regarding the clinical characteristics, radiologic findings, and laboratory findings was collected from the patient’s electronic medical record. The Institutional Review Boards of all participating medical centers reviewed and approved the study protocol.

Definition

Pneumonia was diagnosed by pediatricians based on both physical examinations and radiologic assessments. MP pneumonia was defined as meeting at least one of the following criteria: (1) positive results in both RT-PCR analysis of nasopharyngeal samples and the specific IgM against MP at the time of hospitalization due to CAP, (2) seroconversion of the specific IgM against MP, or (3) four-fold or greater increase in the specific IgG against MP in the acute and convalescent stages [8, 12].
The clinical courses of MP pneumonia have shown heterogeneous features, even in patients with the same in vitro sensitivity to macrolide results [8, 9, 13]. Some previous studies have shown no significant differences in clinical, laboratory, and radiologic features between children with macrolide-resistant MP pneumonia and those with MSMP pneumonia [7-9]. Therefore, to characterize the clinically heterogeneous MP pneumonia into more homogenous clinical groups, we defined clinical MSMP, macrolide less-effective MP (MLEP), and macrolide-refractory MP (MRMP) pneumonia according to fever duration in each pneumonia episode after the initiation of macrolides, regardless of the sensitivity test for macrolides, as follows: fever for less than 3 days, fever for more than 7 days, and more than 3 days but less than 7 days, respectively.

*Microbiological studies*

RT-PCR was performed to identify the causative respiratory viruses using an Anyplex II RV 16 Detection kit (Seegene, Seoul, Korea) [8]. The identified respiratory viruses were as follows: adenovirus (AdV), human rhinovirus (HRV), influenza virus (FLU), parainfluenza virus (PIV), human metapneumovirus (HMPV), respiratory syncytial virus (RSV), bocavirus (BoV), and human coronavirus (HCoV). RT-PCR was performed to identify MP using an ABI 7500 (Applied Biosystems, Foster City, CA, USA) with an EuDxTM-PN MLC Detection Kit (EUDIPIA) and an AnyplexTM II RB5 Detection Kit (Seegene). The results of RT-PCR analyses and serologic titers for MP infections were obtained from comprehensive reviews of laboratory records.

*Statistical analysis*

Seasonal Mann-Kendall tests, a type of non-parametric statistical analysis, were used to detect monotonic trends in monthly data with an annual seasonal pattern. For the
categorical variables, numbers and percentages were calculated and groups were analyzed using the chi-squared test. Post hoc analyses were used to examine if the characteristics of MP pneumonia groups were statistically significant with the chi-squared test. For the parametric continuous variables, means and standard deviations (SD) were derived, and one-way ANOVA tests were conducted to compare groups, followed by Bonferroni’s post hoc test. For the nonparametric continuous variables, the Kruskal-Wallis rank test was performed, followed by Dunn’s post hoc test. All statistical analyses were performed using R 3.5.1. A p value of <0.05 was considered statistically significant.

Results

Characteristics of the study population

A total of 30,994 children with CAP requiring hospitalization were enrolled in the present study. The characteristics of the study population are presented in Table 1. The mean age of the participants was 41.9 months (SD, 40.8 months) and 54.6% of the total study population were boys. The number of children hospitalized due to CAP was highest in fall (September to November), followed by winter (December to February), spring (March to May), and summer (June to August).

Annual and seasonal patterns of CAP caused by respiratory viruses and MP

During the study period, the number of children hospitalized due to CAP was highest in 2011, followed by 2015 (Figure 1). The number of children hospitalized with CAP due to various respiratory virus infections was highest in 2015, with similar seasonal and annual patterns of total CAP. Among the various respiratory viruses, RSV was the most commonly identified virus, especially from November to December, with a gradually increasing trend until each peak (Figure 2). The number of children hospitalized due to FLU-associated CAP peaked from January to March in each year, with the largest number of affected patients
in 2015. The number of children hospitalized with HMPV-associated CAP peaked in April, with its largest number of affected patients in 2014 (Supplementary Figure 1). The two epidemics of MP pneumonia (2011 and 2015) corresponded with the two peaks of CAP. The incidence of MP pneumonia requiring hospitalization in children peaked from October to November in each year (Figure 1). The most common clinical phenotype of MP pneumonia was MSMP, followed by MLEP and MRMP (Figure 3A). During the study period, the monthly rate of MSMP/total MP pneumonia was 63.6-100.0% (mean ± SD, 81.3 ± 7.7), that of MRMP/total MP pneumonia was 0.0-11.0% (4.2 ± 4.3), and that of MLEP/total MP pneumonia was 0.0-30.3% (14.5 ± 14.2) (Figure 3B). The rates of clinical MLEP and MRMP pneumonia showed increasing trends (seasonal Mann-Kendall trend tests, \( P = 0.0644 \) and \( P = 0.0066 \), respectively), whereas the rates of clinical MSMP pneumonia showed a significant reduction during the study period (seasonal Mann-Kendall trend test, \( P = 0.0028 \)).

**Causative pathogens of CAP according to age**

The number of children hospitalized with CAP decreased with age (Table 2). In children younger than 2 years of age, RSV (34.0%) was the most commonly detected respiratory pathogen, followed by PIV (19.7%), and HRV (18.8%). In children 2-4 years of age, RSV (14.9%) was the most commonly identified respiratory virus, followed by HRV (14.8%), and PIV (13.6%). In children 5-17 years of age, HRV (10.6%) was the most commonly detected virus, followed by FLU (9.2%). In children older than 2 years of age, MP (45.3%) was the most common cause of CAP, whereas 9.44% of children younger than 2 years of age exhibited MP infections. The rate of clinical MRMP/total MP pneumonia was highest in children 5-9 years of age (244/3475, 9.8%), followed by adolescents 10-17 years of age (47/905, 6.9%), children 2-4 years of age (154/3526, 4.4%) and those younger than 2
years of age (25/1277, 2.0%).

Clinical characteristics and laboratory findings according to etiologies of CAP

The clinical features and laboratory findings, according to the etiologies, in children admitted due to CAP are described in Table 3. The median length of hospital stay due to CAP was 181.39 hours. The duration of hospitalization due to CAP was longest in those with AdV pneumonia, followed by RSV pneumonia. Systemic corticosteroids were most commonly administered to those with MP pneumonia (1645/7455, 22.1%), followed by RSV pneumonia (622/4521, 13.8%). The number of children with CAP who required oxygen supplementation was greatest in children with RSV pneumonia (905/4521, 20.0%); ventilator care was most commonly applied in children with AdV pneumonia (13/680, 1.9%), followed by those with RSV pneumonia (119/4521, 2.6%).

The whole blood counts were highest in AdV, followed by RSV, FLU, HMPV, and MP. Blood neutrophil percentages were highest in MP, followed by FLU, AdV, HMPV, and RSV. C-reactive protein levels were highest in MP, followed by AdV, HMPV, FLU, and RSV.

Discussion

We evaluated the annual and seasonal patterns in respiratory etiologies of pediatric CAP requiring hospitalization between 2010 to 2015 in a nationwide retrospective cohort study. The most common causes of hospitalization due to pediatric CAP were RSV and MP, with peaks in October-November and November-December, respectively. There were two epidemics of MP pneumonia (2011 and 2015) during the study period. In children hospitalized with CAP due to MP pneumonia, the monthly rates of clinical MRMP and MLEP pneumonias showed increasing trends, together comprising up to 36% of the total cases of MP pneumonia during the study period. In children less than 2 years of age, RSV was the most common cause of pediatric CAP requiring hospitalization, whereas the most common
cause was MP in children older than 2 years, as well as in adolescents. The rate of
children admitted to the intensive care unit was highest in children with RSV pneumonia,
followed by those with AdV pneumonia. Ventilator care was most commonly needed in
children with AdV pneumonia, followed by those with RSV pneumonia. The results of the
present study provide fundamental data on the periodicity of epidemics of pathogens that
cause pediatric CAP requiring hospitalization.
In the present study, we found that RSV was the most common cause of CAP in children
younger than 2 years of age, which is consistent with the findings of other studies
performed in other countries, regardless of the detection methods used or national income
levels of the children who were analyzed [6, 14]. RSV pneumonia was associated with
more severe clinical courses in that the rates of admission to the intensive care unit and
oxygen supplementation were highest, and the rate of ventilator care was the second
highest among children hospitalized with CAP in the present study. The immune response
in RSV infection differs according to age [15]. Notably, inefficient and ineffective immune
responses in early life contribute to more severe clinical courses and higher incidence of
RSV infection; this is especially problematic in infants, who are most frequently affected
by RSV pneumonia [15]. These findings may be valuable to guide therapeutic approaches,
such as application of immune-modulatory drugs for enhancement of immune responses,
and preventive strategies for children with CAP; moreover, the results of the present study
suggest that the development of strategies to prevent RSV infection, especially in infants
and younger children, might aid in decreasing the worldwide disease burden due to CAP.
The number of children hospitalized with MP pneumonia was typically highest between
October and November. In the previous studies, the peak incidence of MP pneumonia
showed a similar pattern to that observed in the present study, regardless of age [14, 16].
However, in the 2011 Korean epidemic, the peak rate of hospitalization due to MP
pneumonia in children occurred in September, whereas the peak rate in the 2015 epidemic occurred in November. In addition, the number of children hospitalized with MP pneumonia in the 2015 epidemic was smaller than that in the 2011 epidemic. These findings were consistent with the results of another study [16]. The reasons for these phenomenon may be associated with exposure to MP in the previous epidemic [7].

Based on in vitro macrolide sensitivity tests, the macrolide resistance rates of MP pneumonia have recently been identified as 50-90% in Asia [7, 8]; these rates differ dramatically among nations. When we defined clinical MSMP, MLEP, and MRMP according to fever duration after the initiation of macrolides in each pneumonia episode, regardless of the results of in vitro macrolide sensitivity tests, the ratios of clinical MLEP and MRMP of total MP pneumonia showed increasing trends after adjustment for monthly time series. However, the estimated clinical MRMP/total MP pneumonia ratio during the study period in the present study (0.0-11.0%) was far lower than that based on in vitro macrolide sensitivity tests (50-90%, especially in Asia) [7, 8]. Therefore, the results of our present study suggest that the clinical response to macrolides in MP pneumonia in the real world might not be as weak as that has been reported, based on in vitro macrolide sensitivity tests, partially due to the self-limiting features of MP infections [17]. Due to the high prevalence of MRMP, there are a great deal of concerns regarding second-line treatment options for MRMP, including tetracycline or fluoroquinolones [7]. Some previous studies have reported no significant differences with respect to clinical and radiologic findings between MRMP and MSMP pneumonia in children [8, 9]. When combined with the results of the present and previous studies [8, 13], a considerable proportion of cases of MRMP pneumonia might be recategorized as clinical MSMP or MLEP pneumonia. Therefore, the first-line treatment for MP pneumonia can be initially started, even in cases of MRMP pneumonia. Considering the exaggerated immune response in children with MP pneumonia
[18], the application of immune-modulators, such as corticosteroids or immunoglobulin, rather than antibiotics, might play a more important role in the management of MP pneumonia, even in some cases of MLEP or MRMP pneumonia [19]. When selecting the proper treatment strategy for MLEP and MRMP pneumonia, consideration of diverse clinical courses, including self-limiting features and combined immune responses in each case, might be more important than the results of in vitro sensitivity tests to macrolide.

This study has some limitations. First, there might have been selection bias due to not including all cases of CAP in Korean children. Second, some patients might have been misclassified into the “no MP pneumonia and no respiratory virus detection” group due to a sampling error, including inappropriate sputum specimens or lack of repetitive follow-up of MP-specific IgM in patients with an initial negative result for MP-specific IgM. Due to the retrospective study design, all techniques of RT-PCR for detection of respiratory viruses and MP and serology for MP were not performed in all participants. In the present study, we did not include CAP caused by typical bacterial pathogens; therefore, we could not identify time-dependent changes in the occurrence of CAP caused by typical bacterial pathogens alone or caused by co-infection of typical bacteria and viruses. However, following the introduction of the pneumococcal conjugate vaccine and the *Haemophilus influenzae* type b vaccine, the disease burden due to bacterial pneumonia has significantly decreased [6, 20]. In the present study, in vitro resistance testing of MP was not performed in some cases. Therefore, we clinically defined the MSMP, MRMP, and MLEP pneumonia groups solely based on fever duration after initiation of the administration of macrolides, regardless of the results of the in vitro tests for macrolide sensitivity. Because the results of in vitro sensitivity tests to antibiotics do not always correspond with those of in vivo sensitivity tests of the same antibiotics [21] and administration of immune-modulators might play a more important role in the treatment of MP pneumonia in some
cases, the application of clinical classifications of MP pneumonia, rather than the results of in vitro macrolide sensitivity tests, might be more helpful in the management of MP pneumonia. This is especially significant in cases of MLEP and MRMP pneumonia, in this era with a high rate of antibiotic-refractory MP.

Conclusions

We identified the annual and seasonal patterns of pediatric CAP requiring hospitalization. Throughout the study period, MP and RSV were the most common causes of CAP, with cyclic peaks in specific seasons. The disease burden due to pediatric CAP requiring hospitalization is largely due to RSV pneumonia, especially in infants and young children. The relatively lower rates of clinical MLEP and MRMP pneumonia, contrary to the known high prevalence of MRMP, highlights the treatment strategies for patients with MP pneumonia. The results of the present study may aid in establishing treatment and management strategies for pediatric CAP and policies to reduce the disease burden by improving public health policies for children.

Abbreviations

AdV: Adenovirus
BoV: Bocavirus
CAP: community acquired pneumonia
FLU: influenza virus
HCoV: Human coronavirus
HMPV: human metapneumovirus
HRV: human rhinovirus
MLEP: macrolide less effective Mycoplasma pneumoniae
MP: Mycoplasma pneumoniae
MRMP: macrolide-refractory *Mycoplasma pneumoniae*

MSMP: macrolide-sensitive *Mycoplasma pneumoniae*

PIV: parainfluenza virus

RSV: respiratory syncytial virus

RT-PCR: real-time polymerase chain reaction

Declarations

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board and Ethics Committee of Soonchunhyang University Seoul Hospital (SCHUH201-309013001). The informed consent was waived because this study was a retrospective medical chart review study with no personal information in each participant.

**Consent for publication**

Not applicable

**Availability of data and materials**

The data used were collected through the routine surveillance systemic of Pneumonia & Respiratory Disease Study Group of Korean Academy of Pediatric Allergy and Respiratory Disease. Data are available from the authors upon reasonable request and with permission of the Pneumonia & Respiratory Disease Study Group of Korean Academy of Pediatric Allergy and Respiratory Disease.

**Competing interests**

The authors declare that they have no competing interests.

**Funding:** This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C2300) and by the Soonchunhyang University Research Fund. This fund provides financial support in the
investigation, design of the study, data collection, data analysis, and interpretation of data.

Authors' contributions

Conceived and designed the experiments: EL, CHK, YJL, HBK, BSK, HYK, YSK, SYK, CRP, JHS, ISS, MSS, MSS, DJS, YMA, HLO, JHY, SSJ, KSL, JSL, GCJ, YYJ, EHC, HLC, SMC, YJC, MYH, JYS, JTK, CCK, and HJY. Performed the experiments: EL, CHK, YJL, HBK, BSK, HYK, YSK, SYK, CRP, JHS, ISS, MSS, MSS, DJS, YMA, HLO, JHY, SSJ, KSL, JSL, GCJ, YYJ, EHC, HLC, SMC, YJC, MYH, JYS, JTK, CCK, and HJY. Contributed reagents/materials/analysis tools: YSK, SYK, and CRP. Contributed to the writing of the manuscript: EL, CHK, CRP and HJY. All authors contributed to manuscript revisions.

Acknowledgements

Not applicable

References

1. Global Burden of Disease Pediatrics Collaboration, Kyu HH, Pinho C, Wagner JA, Brown JC, Bertozzi-Villa A, Charlson FJ, Coffeng LE, Dandona L, Erskine HE et al: Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: Findings from the Global Burden of Disease 2013 Study. JAMA Pediatr 2016, 170(3):267-287.

2. Walker CLF, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE: Global burden of childhood pneumonia and diarrhoea. Lancet 2013, 381(9875):1405-1416.

3. Edmond K, Scott S, Korczak V, Ward C, Sanderson C, Theodoratou E, Clark A, Griffiths U, Rudan I, Campbell H: Long term sequelae from childhood pneumonia; systematic review and meta-analysis. PLoS One 2012, 7(2):e31239.

4. GBD 2015 LRI Collaborators: Estimates of the global, regional, and national
morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis* 2017, **17**(11):1133-1161.

5. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C *et al*: Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* 2017, **390**(10098):946-958.

6. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH *et al*: Community-acquired pneumonia requiring hospitalization among U.S. children. *N Engl J Med* 2015, **372**(9):835-845.

7. Yamazaki T, Kenri T: Epidemiology of *Mycoplasma pneumoniae* Infections in Japan and Therapeutic Strategies for Macrolide-Resistant *M. pneumoniae*. *Front Microbiol* 2016, **7**:693.

8. Lee E, Cho HJ, Hong SJ, Lee J, Sung H, Yu J: Prevalence and clinical manifestations of macrolide resistant *Mycoplasma pneumoniae* pneumonia in Korean children. *Korean J Pediatr* 2017, **60**(5):151-157.

9. Kim JH, Kim JY, Yoo CH, Seo WH, Yoo Y, Song DJ, Choun JG: Macrolide resistance and its impacts on *M. pneumoniae* pneumonia in children: Comparison of two recent epidemics in Korea. *Allergy Asthma Immunol Res* 2017, **9**(4):340-346.

10. Waites KB, Talkington DF: *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev* 2004, **17**(4):697-728, table of contents.

11. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T: Clinical evaluation of macrolide-resistant *Mycoplasma*
**pneumoniae.** *Antimicrob Agents Chemother* 2006, **50**(2):709-712.

12. Cho YJ, Han MS, Kim WS, Choi EH, Choi YH, Yun KW, Lee S, Cheon JE, Kim IO, Lee HJ: *Correlation between chest radiographic findings and clinical features in hospitalized children with Mycoplasma pneumoniae pneumonia.* *PLoS One* 2019, **14**(8):e0219463.

13. Kim YJ, Shin KS, Lee KH, Kim YR, Choi JH: *Clinical characteristics of macrolide-resistant Mycoplasma pneumoniae from children in Jeju.* *J Korean Med Sci* 2017, **32**(10):1642-1646.

14. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, Luksic I, Fischer Walker CL, Black RE, Campbell H et al: *Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries.* *J Glob Health* 2013, **3**(1):010401.

15. Ruckwardt TJ, Morabito KM, Graham BS: *Determinants of early life immune responses to RSV infection.* *Curr Opin Virol* 2016, **16**:151-157.

16. Qu J, Yang C, Bao F, Chen S, Gu L, Cao B: *Epidemiological characterization of respiratory tract infections caused by Mycoplasma pneumoniae during epidemic and post-epidemic periods in North China, from 2011 to 2016.* *BMC Infect Dis* 2018, **18**(1):335.

17. Meyer Sauteur PM, Unger WW, Nadal D, Berger C, Vink C, van Rossum AM: *Infection with and Carriage of Mycoplasma pneumoniae in Children.* *Front Microbiol* 2016, **7**:329.

18. Zhang Y, Mei S, Zhou Y, Huang M, Dong G, Chen Z: *Cytokines as the good predictors of refractory Mycoplasma pneumoniae pneumonia in school-aged children.* *Sci Rep* 2016, **6**:37037.
19. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH: Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. *Allergy Asthma Immunol Res* 2014, 6(1):22-26.

20. Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H et al: Burden of Streptococcus pneumoniae and *Haemophilus influenzae* type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. *Lancet Glob Health* 2018, 6(7):e744-e757.

21. Pereyre S, Goret J, Bebear C: *Mycoplasma pneumoniae*: Current knowledge on macrolide resistance and treatment. *Front Microbiol* 2016, 7:974.

### Tables

**Table 1. Demographic characteristics of hospitalized children with community-acquired pneumonia**

| Variables                     | No. (%) or mean ± SD |
|-------------------------------|----------------------|
| Number                        | 30,994               |
| Age (mo), mean ± SD           | 41.9 ± 40.8          |
| < 2 yrs                       | 13,527 (43.6)        |
| 2 yrs ≤ age <5 yrs            | 9,715 (31.3)         |
| 5 yrs ≤ age <12 yrs           | 5,802 (18.7)         |
| 12 yrs ≤ age <18 yrs          | 1,950 (6.3)          |
| Sex (male), No. (%)           | 16,929 (54.6)        |
| Incident year, No. (%)        | 30,991 (100.0)       |
| 2010                          | 4,001 (12.9)         |
| 2011                          | 6,427 (20.7)         |
| 2012                          | 3753 (12.1)          |
| 2013                          | 2913 (9.4)           |
| 2014                          | 5702 (18.4)          |
| 2015                          | 8195 (26.4)          |
| Incident season               | 30,994 (100.0)       |
| Spring (Mar, Apr, May)        | 7765 (25.1)          |
| Summer (Jun, Jul, Aug)        | 5124 (16.5)          |
| Fall (Sep, Oct, Nov)          | 10,065 (32.5)        |
| Winter (Dec, Jan, Feb)        | 8,040 (25.9)         |

Mo, months; n, number; SD, standard deviation, yrs, years.
### Table 2. Prevalence of causative respiratory viruses and *Mycoplasma pneumoniae* according to age groups in children hospitalized due to community-acquired pneumonia

| Detected respiratory virus | <2 years, No. (%) | 2-4 years, No. (%) | 5-11 years, No. (%) | 12-17 years, No. (%) | Total, N (%) |
|---------------------------|------------------|-------------------|-------------------|-------------------|------------|
| Adenovirus                | 964 (7.1)        | 764 (7.9)         | 183 (3.12)        | 33 (1.7)         | 1,944 (6.3) |
| Rhinovirus                | 2,545 (18.8)     | 1,441 (14.8)      | 626 (10.8)        | 199 (10.2)       | 4,811 (15.5)|
| Influenza                 | 701 (5.2)        | 619 (6.44)        | 519 (9.0)         | 196 (10.1)       | 2,035 (6.6) |
| Influenza A               | 534 (4.0)        | 386 (4.0)         | 302 (5.2)         | 117 (6.0)        | 1,339 (4.3) |
| Influenza B               | 172 (1.3)        | 239 (2.5)         | 218 (3.8)         | 79 (4.1)         | 708 (2.3)  |
| Parainfluenza             | 2,668 (19.7)     | 1,317 (13.6)      | 476 (8.2)         | 192 (9.9)        | 4,653 (15.3)|
| Metapneumovirus           | 1,049 (7.8)      | 750 (7.7)         | 112 (1.9)         | 45 (2.3)         | 1,956 (6.4)|
| Respiratory syncytial virus | 4,600 (34.0)   | 1,451 (14.9)      | 194 (3.3)         | 59 (3.0)         | 6,304 (20.8)|
| Bocavirus                 | 511 (38.0)       | 214 (2.2)         | 41 (0.7)          | 20 (1.0)         | 786 (2.6)  |
| Coronavirus               | 264 (2.0)        | 152 (1.6)         | 66 (1.1)          | 21 (1.1)         | 503 (1.6)  |
| MP                        | 1,277 (9.4)      | 3,526 (36.3)      | 3,475 (59.9)      | 905 (46.4)       | 9,183 (30.2)|
| Clinically MSMP           | 1,121 (8.3)      | 2,816 (29.0)      | 2,482 (42.8)      | 681 (34.9)       | 7,100 (23.1)|
| Clinically MRMP           | 25 (0.2)         | 154 (1.6)         | 244 (4.2)         | 47 (2.4)         | 470 (1.5)  |
| Clinically MLEP           | 131 (1.1)        | 556 (5.7)         | 749 (12.9)        | 177 (9.1)        | 1,613 (5.2) |
| Neither MP nor virus identified | 1,997 (14.8) | 1,529 (15.7)      | 906 (15.6)        | 484 (24.8)       | 4,916 (16.0)|
| Only respiratory virus detection | 10,253 (75.8)| 4,660 (48.0)      | 1,421 (24.5)      | 561 (28.8)       | 16,895     |
| Total number              | 13,527 (100.0)   | 9,715 (100.0)     | 5,802 (100.0)     | 1,950 (100.0)    | 30,994     |

MLEP, macrolide less effective *Mycoplasma pneumoniae*; MP, *Mycoplasma pneumoniae*; MRMP, macrolide refractory *Mycoplasma pneumoniae*; MSMP, macrolide sensitive *Mycoplasma pneumoniae*; No., Number

### Table 3. Comparison of clinical and laboratory findings according to respiratory pathogens in children hospitalized due to community-acquired pneumonia
### Variables

| Variables                                   | only MP$^1$ (n=7455) | MP coinfected with virus$^2$ (n=1728) | Adenovirus$^3$ (n=680) | Influenza virus (n=1491) |
|---------------------------------------------|-----------------------|--------------------------------------|-------------------------|--------------------------|
| Age (month), mean ± SD                      | 66.7 ± 39.7           | 53.3 ± 37.3                          | 34.1 ± 28.0             | 54.4 ± 46.0              |
| Sex (male), No. (%)                         | 3,680 (49.4)          | 862 (49.9)                           | 389 (57.2)              | 828 (55.5)               |
| Duration of Hospitalization (hrs), mean ± SD| 159.9 ± 227.4         | 174.2 ± 339.8                        | 181.4 ± 250.4           | 136.3 ± 161.2            |
| Administration of steroid, No. (%)          | 1,645 (22.1)          | 454 (26.3)                           | 75 (11.0)               | 117 (7.9)                |
| Oxygen supplementation, No. (%)             | 299 (4.0)             | 109 (6.3)                            | 67 (9.9)                | 82 (5.5)                 |
| Ventilator care, No. (%)                    | 12 (0.2)              | 4 (0.2)                              | 8 (1.2)                 | 14 (0.9)                 |
| ICU care, No. (%)                           | 27 (0.4)              | 11 (0.6)                             | 13 (1.9)                | 23 (1.5)                 |
| WBC (x10$^3$/μL), median ± IQR              | 8275 ± 4700           | 8870 ± 5560                          | 11810 ± 7155            | 7510 ± 4760              |
| Neutrophil (%), median ± IQR                | 60.1 ± 21.8           | 57.6 ± 26.2                          | 56.2 ± 25.8             | 57.5 ± 32.2              |
| Lymphocyte (%), median ± IQR                | 28.5 ± 18.8           | 31 ± 22.8                            | 33 ± 25                 | 29.7 ± 28                |
| Eosinophil (%), median ± IQR                | 1.6 ± 3.3             | 1.1 ± 2.5                            | 0.4 ± 1.4               | 0.4 ± 1                  |
| Hb, median ± IQR                            | 12.4 ± 1.2            | 12.3 ± 1.2                           | 11.8 ± 1.2              | 12.3 ± 1.5               |
| Platelet (x10$^3$/μL), median ± IQR         | 293.0 ± 140.0         | 284.0 ± 126.0                        | 297.0 ± 144.8           | 232.0 ± 102.0            |
| AST, U/L, median ± IQR                      | 29.0 ± 9.0            | 30.0 ± 9.0                           | 31.0 ± 8.0              | 31.0 ± 9.0               |
| ALT, U/L, median ± IQR                      | 14.0 ± 7.0            | 14.0 ± 7.0                           | 14.0 ± 8.0              | 15.0 ± 9.0               |
| LDH, U/L, median ± IQR                      | 479.0 ± 294.5         | 475.0 ± 348.5                        | 516.5 ± 326.8           | 467.0 ± 292.5            |
| CRP, mg/dL, median ± IQR                    | 2.2 ± 4.8             | 1.6 ± 3.8                            | 2.7 ± 4.9               | 1.0 ± 2.6                |
| ESR, mm/hr, median ± IQR                    | 31.0 ± 30.0           | 30.0 ± 30.0                          | 34.0 ± 35.0             | 14.0 ± 19.2              |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Hb, hemoglobin; ICU, intensive care unit; LDH, lactate dehydrogenase; MP, Mycoplasma pneumoniae; NA, not applicable; RSV, respiratory syncytial virus; SD, standard deviation; WBC, whole blood count.

\textsuperscript{a}Group 1, MP pneumonia; group 2, MP co-infected with virus; group 3, adenovirus; group 4, influenza virus; group 5, Metapneumovirus; group 6, RSV; The inequality or equal signs mean the rank order of post hoc analyses.

\textsuperscript{b}Post hoc analyses were used to examine if the characteristics of MP pneumonia groups were statistically significant with chi-squared test. For the continuous variables, one-way ANOVA tests were conducted to compare groups, followed by Mann-Whitney U test.

### Figures
Number of children hospitalized with community-acquired pneumonia according to etiology between 2011 and 2015 in Korea
Figure 2

Number of children hospitalized with community acquired pneumonia according to etiology
Time-dependent changes in the numbers of children hospitalized due to *Mycoplasma pneumoniae* (MP) pneumonia pneumonia according to clinical macrolide sensitivity. (A) Number of children hospitalized with MP pneumonia
classified as macrolide-sensitive (MSMP), macrolide-refractory (MRMP), and macrolide less-effective (MLEP). (B) Time-dependent changes in the ratios of MSMP/total MP pneumonia, MRMP pneumonia/total MP pneumonia, and MLEP pneumonia/total MP pneumonia during the study period.

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Supplementary Figure legend.doc
Figure suppl 1.tif